Electrocardiography in two models of isoproterenol-induced left ventricular remodelling

Physiological Research

Volumn 57, Issue SUPPL. 2, 2008, Pages

  Králová, Eva ^a   Mokran T ^a   Murin J ^a   Stankovicova T ^a  

^a Faculty of Natural Sciences   (Slovakia)

Author keywords

Electrocardiography; Isoproterenol; Rat; Ventricular remodelling

Indexed keywords

EID: 45849094003     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. AKAZAWA H, KUMURO I: Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92: 1079-1088, 2003.
2. ALFAKIH K, WALTERS K, JONES T, RIDGWAY J, HALL AS, SIVANANTHAN M: New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Hypertension 44: 175-9, 2004.
3. ANDRADE ZA, ANDRADE SG, OLIVEIRA GB, AND ALONSO DR: Histopathology of the conducting tissue of the heart in Chagas' myocarditis. Am Heart J 95: 316-324, 1978.
4. ARMOUNDAS AA, WU R, JUANG G, MARBÁN E, TOMASELLI GF: Electrical and structural remodeling of the failing ventricle. Pharmacol Ther 92: 213-230, 2001.
5. BACHAROVA L, MICHALAK K, KYSELOVIC J, KLIMAS J: Relation between QRS amplitude and left ventricular mass in the initial stage of exercise-induced left ventricular hypertrophy in rats. Clin Exp Hypertens 27: 533-541, 2005.
6. BAILLARD C, MANSIER P, ENNEZAT PV, MANGIN L, MEDIGUE C, SWYNGHEDAUW B, CHEVALIER B: Converting enzyme inhibition normalizes QT interval in spontaneously hypertensive rats. Hypertension 36: 350-354, 2000.
7. BÉNITAH JP, KERFANT BG, VASSORT G, RICHARD S, GÓMEZ A M: Altered communication between L-type calcium channels and ryanodine receptors in heart failure. Front in Bioscience 7: 263-275, 2002.
8. DENARIE N, LINHART A, LEVENSON J, SIMON A.: Utility of electrocardiogram for predicting increased left ventricular mass in asymptomatic men at risk for cardiovascular disease. Am J Hypertens 11: 861-865,1998.
9. DRITSAS A, SBAROUNI E, GILLIGAN D, NIHOYANNOPOULOS P, OAKLEY CM: QT interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 15: 739-742, 1992.
10. GALINER M, BALANESCU S, FOURCADE J, DOROBANTU M, BOVEDA S, MASSABUAU P, CABROL P, DONGAY B, FAUVEL JM, BOUNHOURE JP: Prognostic value of ventricular arrhythmias in systemic hypertension. J Hypertens 15: 1779-1783, 1997.
11. GIMA K, RUDY Y: Ionic current basis of electrocardiographic waveforms: a model study. Circ Res 90: 889-896, 2002.
12. GOLDSPINK DF, BURNISTOB JG, ELLISON GM, CLARK WA, TAN LB: Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol 89: 407- 416, 2004.
13. GRIMM D, ELSNER D, SCHUNKERT H, PFEIFER M, GRIESE D, BRUCKSCHLEGEL G, MUDERS F, RIEGGER GA, KROMER EP: Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res 37: 91-100, 1998.
14. JALIL JE, JANICKI JS, PICK R ABRAHAMS C, WEER KT: Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ Res 65: 258-264, 1989.
15. KAHN DS, RONA G, CHAPPEL CI: Isoproterenol - induced cardiac necrosis. Ann NY Acad Sci 156: 285-289,1969.
16. KAYE D, ESLER M: Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res 66: 256-264, 2005.
17. KOHUTOVA R, POGRANOVA S, JUSKO M, SVEC P, STANKOVICOVA T: Electrical activity of the heart in the rats with experimental hypertension. Physiol Res 55: 3P, 2006.
18. KRALOVA E, KORENOVA L, KOHUTOVA R, JUSKO M, SVEC P, PECHANOVA O, BERNATOVA I, STANKOVICOVA T: Is increased susceptibility to ventricular arrhythmias in hypertensive rats? Physiol Res 56: 18P, 2007.
19. KŘENEK P, KLIMAS J, KROSLAKOVÁ M, GAZOVÁ A, PLANDOROVÁ J, KUČEROVÁ D, FECENKOVA A, ŠVEC P, KYSELOVIČ J: Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol 84: 1245-1250, 2006.
20. LEENEN FHH, WHITE R, YUAN, B: Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol 281: H2410-2416, 2001.
21. MAZZOLENI A, CURTIN ME, WOLFF R, REINER L, SOMES G: On the relationship between heart weights, fibrosis, and QRS duration. J Electrocardiol 8: 233-236, 1975.
22. MESZAROS J, KHANANSHVILI D, HART G: Mechanisms underlying delayed afterdepolarizations in hypertrophied left ventricular myocytes of rats. Am J Physiol Heart Circ Physiol 281: H903-914, 2001.
23. MÉSZÁROS J, PÁSZTOR B: Effect of ouabain in catecholamine-induced cardiac hypertrophy. Acta Physiol Hung 83: 55-62, 1995.
24. NORMAN JE JR, LEVY D: Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol 26: 1022-1029, 1995.
25. OIKARINEN L, NIEMINEN MS, TOIVONEN L, VIITASALO M, WACHTELL K, PAPADEMETRIOU V, JERN S, DAHLOF B, DEVEREUX RB, OKIN PM; LIFE STUDY INVESTIGATORS: Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. Am Heart J 145: 919-925, 2003.
26. OIKARINEN L, NIEMINEN MS, VIITASALO M, TOIVONEN L, JERN S, DAHLOF B, DEVEREUX RB, OKIN PM; LIFE STUDY INVESTIGATORS: QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 43: 1029-1034, 2004.
27. OKIN PM, DEVEREUX RB, JERN S, KJELDSEN SE, JULIUS S, NIEMINEN MS, SNAPINN S, HARRIS KE, AURUP P, EDELMAN JM, DAHLOF B: Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 108: 684-690, 2003.
28. OKIN PM, DEVEREUX RB, NIEMINEN MS, JERN S, OIKARINEN L, VIITASALO M, TOIVONEN L, KJELDSEN SE, JULIUS S, SNAPINN S, DAHLÖF B: Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 44: 48-54, 2004.
29. OZAKI M, KAWASHIMA S, YAMASHITA T, HIRASE T, OBASHI Y, INOUE N, HIRATA K, YOKOYAMA M: Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 66: 851-856, 2002.
30. RONA G, CHAPPEL CI, BALASZ T, GAUDRY R: An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch Pathol 67: 443- 445, 1959 a.
31. RONA G, ZSOTER T, CHAPPEL C, GAUDRY R: Myocardial lesions, circulatory and electrocardiographic changes produced by isoproterenol in the dog. Rev Can Biol 18: 83-94, 1959 b.
32. SIA YT, PARKER TG, TSOPORIS JN, LIU P, ADAM A, ROULEAU JL: Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharmacol 39: 73-78, 2002. ŠIMKO F: Left ventricular hypertrophy regression as process variable biological implications. Can J Cardiol 12: 507-512, 1998.
33. ŠIMKO F: Is NO the king? Pathophysiological benefit with uncertain clinical impact. Physiol Res in press 2007.
34. TEERLINK JR, PFEFFER JM, PFEFFER MA: Progressive ventricular remodeling in response to diffuse isoproterenol -induced myocardial necrosis in rats. Circ Res 75: 105-113, 1994.
35. TUREK Z, KALUS M, POUPA O: The effect of isoprenaline pretreatment on the size of acute myocardial necrosis induced by the same drug. Physiol Bohemoslov 15: 353, 1966.
36. YAMORI Y, OHTAKA M, NARA Y: Vectorcardiographic study on left ventricular hypertrophy in spontaneously hypertensive rats. Jpn Circ J 40: 1315-29, 1976.
37. YAN GX, ANTZELEVITCH C: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98: 1928-1936, 1998.